{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:19:21Z","timestamp":1783635561980,"version":"3.55.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11095-026-04020-8","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:39:13Z","timestamp":1771547953000},"page":"1745-1761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanotherapeutics to Overcome Chemotherapy Resistance in Ovarian Cancer"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0528-2732","authenticated-orcid":false,"given":"Shaheen","family":"Mahira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshini","family":"Sathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahaman","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Pamula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"4020_CR1","doi-asserted-by":"crossref","unstructured":"McGuire WP, 3rd and Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer. 2003;89 Suppl 3(Suppl 3): S3\u20138.","DOI":"10.1038\/sj.bjc.6601494"},{"issue":"8","key":"4020_CR2","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.3390\/ijms23084249","volume":"23","author":"R Tal\u00e9ns-Visconti","year":"2022","unstructured":"Tal\u00e9ns-Visconti R, D\u00edez-Sales O, de Juli\u00e1n-Ortiz JV, N\u00e1cher A. Nanoliposomes in cancer therapy: marketed products and current clinical trials. Int J Mol Sci. 2022;23(8):4249.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"4020_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66.","journal-title":"Mol Cancer"},{"key":"4020_CR4","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8293","author":"L Yang","year":"2022","unstructured":"Yang L, et al. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (review). Oncol Rep. 2022. https:\/\/doi.org\/10.3892\/or.2022.8293.","journal-title":"Oncol Rep"},{"key":"4020_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010183","author":"M Eslami","year":"2024","unstructured":"Eslami M, et al. Overcoming chemotherapy resistance in metastatic cancer: a comprehensive review. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12010183.","journal-title":"Biomedicines"},{"issue":"2","key":"4020_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11095-008-9735-8","volume":"26","author":"S Shukla","year":"2009","unstructured":"Shukla S, et al. Curcumin inhibits the activity of ABCG2\/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009;26(2):480\u20137.","journal-title":"Pharm Res"},{"issue":"10","key":"4020_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3109\/1061186X.2013.837469","volume":"21","author":"B Aslan","year":"2013","unstructured":"Aslan B, et al. Nanotechnology in cancer therapy. J Drug Target. 2013;21(10):904\u201313.","journal-title":"J Drug Target"},{"issue":"41","key":"4020_CR8","first-page":"2300666","volume":"20","author":"S Torres Quintas","year":"2024","unstructured":"Torres Quintas S, et al. Nanotherapeutics in women\u2019s health emerging nanotechnologies for triple-negative breast cancer treatment. Small. 2024;20(41):2300666.","journal-title":"Small"},{"issue":"9","key":"4020_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351.","journal-title":"Nat Biotechnol"},{"key":"4020_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1492546","volume":"15","author":"C Guan","year":"2024","unstructured":"Guan C, et al. Nanomaterials: breaking the bottleneck of breast cancer drug resistance. Front Immunol. 2024;15:1492546.","journal-title":"Front Immunol"},{"key":"4020_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1296091","volume":"14","author":"I Waheed","year":"2024","unstructured":"Waheed I, et al. Lipid-based nanoparticles as drug delivery carriers for cancer therapy. Front Oncol. 2024;14:1296091.","journal-title":"Front Oncol"},{"issue":"6","key":"4020_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1089\/adt.2024.019","volume":"22","author":"S Chauhan","year":"2024","unstructured":"Chauhan S, Nagpal K. Latest delivery advancements of lipid nanoparticles for cancer treatment. Assay Drug Dev Technol. 2024;22(6):340\u201360.","journal-title":"Assay Drug Dev Technol"},{"key":"4020_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092137","author":"DL Gbian","year":"2022","unstructured":"Gbian DL, Omri A. Lipid-based drug delivery systems for diseases managements. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10092137.","journal-title":"Biomedicines"},{"issue":"6","key":"4020_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201803703","volume":"15","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, et al. Holo-lactoferrin modified liposome for relieving tumor hypoxia and enhancing radiochemotherapy of cancer. Small. 2019;15(6):e1803703.","journal-title":"Small"},{"issue":"11","key":"4020_CR15","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1039\/C5SM02958A","volume":"12","author":"A Gupta","year":"2016","unstructured":"Gupta A, et al. Nanoemulsions: formation, properties and applications. Soft Matter. 2016;12(11):2826\u201341.","journal-title":"Soft Matter"},{"key":"4020_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2147\/IJN.S124158","volume":"12","author":"JE Kim","year":"2017","unstructured":"Kim JE, Park YJ. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer. Int J Nanomedicine. 2017;12:645\u201358.","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"4020_CR17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2217\/nnm-2018-0046","volume":"13","author":"Y Su","year":"2018","unstructured":"Su Y, et al. Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy. Nanomedicine. 2018;13(9):1009\u201323.","journal-title":"Nanomedicine"},{"issue":"2\u20133","key":"4020_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejphar.2011.09.023","volume":"670","author":"S Parveen","year":"2011","unstructured":"Parveen S, Sahoo SK. Long circulating chitosan\/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol. 2011;670(2\u20133):372\u201383.","journal-title":"Eur J Pharmacol"},{"key":"4020_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ijbiomac.2016.11.098","volume":"95","author":"MM Badran","year":"2017","unstructured":"Badran MM, et al. Preparation and characterization of polymeric nanoparticles surface modified with chitosan for target treatment of colorectal cancer. Int J Biol Macromol. 2017;95:643\u20139.","journal-title":"Int J Biol Macromol"},{"key":"4020_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.990505","volume":"13","author":"D Zhang","year":"2022","unstructured":"Zhang D, et al. Drug-loaded PEG-PLGA nanoparticles for cancer treatment. Front Pharmacol. 2022;13:990505.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4020_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s42003-020-0817-4","volume":"3","author":"L Palanikumar","year":"2020","unstructured":"Palanikumar L, et al. Ph-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. Commun Biol. 2020;3(1):95.","journal-title":"Commun Biol"},{"key":"4020_CR22","first-page":"100048","volume":"7","author":"Y Herdiana","year":"2022","unstructured":"Herdiana Y, et al. Scale-up polymeric-based nanoparticles drug delivery systems: development and challenges. Open Nano. 2022;7:100048.","journal-title":"Open Nano"},{"key":"4020_CR23","doi-asserted-by":"publisher","first-page":"102314","DOI":"10.1016\/j.nantod.2024.102314","volume":"56","author":"MM Mahmud","year":"2024","unstructured":"Mahmud MM, et al. Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials. Nano Today. 2024;56:102314.","journal-title":"Nano Today"},{"key":"4020_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.707319","volume":"9","author":"D Chang","year":"2021","unstructured":"Chang D, et al. Stimuli-responsive polymeric nanoplatforms for cancer therapy. Front Bioeng Biotechnol. 2021;9:707319.","journal-title":"Front Bioeng Biotechnol"},{"issue":"11","key":"4020_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2024.109562","volume":"35","author":"T Hu","year":"2024","unstructured":"Hu T, et al. Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chin Chem Lett. 2024;35(11):109562.","journal-title":"Chin Chem Lett"},{"key":"4020_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071932","author":"PT Villalobos Gutierrez","year":"2023","unstructured":"Villalobos Gutierrez PT, et al. Functionalized metal nanoparticles in cancer therapy. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071932.","journal-title":"Pharmaceutics"},{"key":"4020_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.colsurfb.2019.01.010","volume":"176","author":"HT Nguyen","year":"2019","unstructured":"Nguyen HT, et al. Transferrin-conjugated pH-sensitive platform for effective delivery of porous palladium nanoparticles and paclitaxel in cancer treatment. Colloids Surf B Biointerfaces. 2019;176:265\u201375.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4020_CR28","doi-asserted-by":"crossref","unstructured":"Nowak-Jary J, Plociennik A, Machnicka B. Functionalized magnetic Fe(3)O(4) nanoparticles for targeted methotrexate delivery in ovarian cancer therapy. Int J Mol Sci. 2024;25(16).","DOI":"10.3390\/ijms25169098"},{"key":"4020_CR29","doi-asserted-by":"publisher","first-page":"1129768","DOI":"10.3389\/fbioe.2023.1129768","volume":"11","author":"E Khakpour","year":"2023","unstructured":"Khakpour E, et al. Graphene-based nanomaterials for stimuli-sensitive controlled delivery of therapeutic molecules. Front Bioeng Biotechnol. 2023;11:1129768.","journal-title":"Front Bioeng Biotechnol"},{"issue":"5","key":"4020_CR30","first-page":"1949","volume":"6","author":"D Goren","year":"2000","unstructured":"Goren D, et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 2000;6(5):1949\u201357.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4020_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12935-024-03469-0","volume":"24","author":"A Romaniuk-Drapala","year":"2024","unstructured":"Romaniuk-Drapala A, et al. Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells. Cancer Cell Int. 2024;24(1):285.","journal-title":"Cancer Cell Int"},{"key":"4020_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jconrel.2024.05.005","volume":"371","author":"CA Juul","year":"2024","unstructured":"Juul CA, et al. HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model. J Control Release. 2024;371:288\u201397.","journal-title":"J Control Release"},{"key":"4020_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/581363","volume":"2012","author":"GP Stathopoulos","year":"2012","unstructured":"Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv. 2012;2012:581363.","journal-title":"J Drug Deliv"},{"issue":"9","key":"4020_CR34","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1007\/s11095-014-1345-z","volume":"31","author":"S Ganta","year":"2014","unstructured":"Ganta S, et al. Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm Res. 2014;31(9):2490\u2013502.","journal-title":"Pharm Res"},{"key":"4020_CR35","doi-asserted-by":"publisher","first-page":"119655","DOI":"10.1016\/j.ijpharm.2020.119655","volume":"587","author":"AC Groo","year":"2020","unstructured":"Groo AC, et al. Pyridoclax-loaded nanoemulsion for enhanced anticancer effect on ovarian cancer. Int J Pharm. 2020;587:119655.","journal-title":"Int J Pharm"},{"key":"4020_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1526718","volume":"15","author":"T You","year":"2025","unstructured":"You T, Zhang S. Recent advances in PLGA polymer nanocarriers for ovarian cancer therapy. Front Oncol. 2025;15:1526718.","journal-title":"Front Oncol"},{"key":"4020_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041206","author":"CE Jin","year":"2023","unstructured":"Jin CE, et al. Synergistic encapsulation of paclitaxel and sorafenib by methoxy poly(ethylene glycol)-b-poly(caprolactone) polymeric micelles for ovarian cancer therapy. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15041206.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4020_CR38","doi-asserted-by":"publisher","first-page":"e10325","DOI":"10.1002\/btm2.10325","volume":"8","author":"M Ashrafizadeh","year":"2023","unstructured":"Ashrafizadeh M, et al. Chitosan-based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy. Bioeng Transl Med. 2023;8(1):e10325.","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"4020_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/abcr.2025.141001","volume":"14","author":"D Yara","year":"2025","unstructured":"Yara D, Oroszi T. Understanding breast cancer: a comprehensive review of epidemiology, risk factors, and treatment strategies. Adv Breast Cancer Res. 2025;14(1):1\u201315.","journal-title":"Adv Breast Cancer Res"},{"key":"4020_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E P\u00e9rez-Herrero","year":"2015","unstructured":"P\u00e9rez-Herrero E, Fern\u00e1ndez-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52\u201379.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"4020_CR41","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/pharmaceutics15020622","volume":"15","author":"H Sun","year":"2023","unstructured":"Sun H, et al. mRNA-based therapeutics in cancer treatment. Pharmaceutics. 2023;15(2):622.","journal-title":"Pharmaceutics"},{"issue":"10","key":"4020_CR42","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen CL, et al. Clinical advances and ongoing trials of mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23(10):e450\u20138.","journal-title":"Lancet Oncol"},{"key":"4020_CR43","doi-asserted-by":"publisher","DOI":"10.37285\/ijpsn.2015.8.1.2","author":"V Kaur","year":"2015","unstructured":"Kaur V, et al. Surface modified nanoparticulate carriers for the targeted treatment of breast cancer. Int J Pharm Sci Nanotechnol. 2015. https:\/\/doi.org\/10.37285\/ijpsn.2015.8.1.2.","journal-title":"Int J Pharm Sci Nanotechnol"},{"issue":"1","key":"4020_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1039\/c2ib20104f","volume":"5","author":"AH Stegh","year":"2013","unstructured":"Stegh AH. Toward personalized cancer nanomedicine\u2013past, present, and future. Integr Biol (Camb). 2013;5(1):48\u201365.","journal-title":"Integr Biol (Camb)"},{"issue":"12","key":"4020_CR45","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.3390\/cancers13122898","volume":"13","author":"C Corti","year":"2021","unstructured":"Corti C, et al. Antibody\u2013drug conjugates for the treatment of breast cancer. Cancers (Basel). 2021;13(12):2898.","journal-title":"Cancers (Basel)"},{"key":"4020_CR46","first-page":"11","volume":"8","author":"\u00c9A Larose","year":"2025","unstructured":"Larose \u00c9A, et al. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. Cancer Drug Resistance. 2025;8:11.","journal-title":"Cancer Drug Resistance"},{"issue":"8","key":"4020_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082223","volume":"12","author":"A Manzano","year":"2020","unstructured":"Manzano A, Oca\u00f1a A. Antibody-drug conjugates: a promising novel therapy for the treatment of ovarian cancer. Cancers (Basel). 2020;12(8):2223.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"4020_CR48","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.3390\/cancers16142545","volume":"16","author":"S Sato","year":"2024","unstructured":"Sato S, et al. Antibody-drug conjugates: the new treatment approaches for ovarian cancer. Cancers (Basel). 2024;16(14):2545.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4020_CR49","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/14712598.2020.1776253","volume":"21","author":"CA Calo","year":"2021","unstructured":"Calo CA, O\u2019Malley DM. Antibody-drug conjugates for the treatment of ovarian cancer. Expert Opin Biol Ther. 2021;21(7):875\u201387.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"4020_CR50","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.2217\/fon.09.126","volume":"5","author":"I-M Shih","year":"2009","unstructured":"Shih I-M, Davidson B. Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol. 2009;5(10):1641\u201357.","journal-title":"Future Oncol"},{"issue":"6","key":"4020_CR51","doi-asserted-by":"publisher","first-page":"e99687","DOI":"10.1371\/journal.pone.0099687","volume":"9","author":"SL Lim","year":"2014","unstructured":"Lim SL, et al. Overexpression of piRNA pathway genes in epithelial ovarian cancer. PLoS One. 2014;9(6):e99687.","journal-title":"PLoS One"},{"issue":"1","key":"4020_CR52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KR Cho","year":"2009","unstructured":"Cho KR, Shih I-M. Ovarian cancer. Annu Rev Pathol Mech Dis. 2009;4(1):287\u2013313.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"3","key":"4020_CR53","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/carcin\/bgab010","volume":"42","author":"P Giamougiannis","year":"2021","unstructured":"Giamougiannis P, Martin-Hirsch PL, Martin FL. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia. Carcinogenesis. 2021;42(3):327\u201343.","journal-title":"Carcinogenesis"},{"issue":"2","key":"4020_CR54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","volume":"12","author":"R Hassan","year":"2006","unstructured":"Hassan R, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447\u201353.","journal-title":"Clin Cancer Res"},{"key":"4020_CR55","volume":"28","author":"A Nurgalieva","year":"2021","unstructured":"Nurgalieva A, et al. Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer. Biochem Biophys Rep. 2021;28:101104.","journal-title":"Biochem Biophys Rep"},{"issue":"23","key":"4020_CR56","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162\u201374.","journal-title":"N Engl J Med"},{"issue":"5","key":"4020_CR57","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert JM, Morris CQ. Antibody\u2013drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34(5):1015\u201335.","journal-title":"Adv Ther"},{"issue":"3","key":"4020_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). 2023;15(3):713.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4020_CR59","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","volume":"15","author":"S Li","year":"2025","unstructured":"Li S, et al. Resistance to antibody\u2013drug conjugates: a review. Acta Pharm Sin B. 2025;15(2):737\u201356.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"4020_CR60","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3390\/pharmaceutics14051113","volume":"14","author":"TA Seidu","year":"2022","unstructured":"Seidu TA, et al. Functionalization of nanoparticulate drug delivery systems and its influence in cancer therapy. Pharmaceutics. 2022;14(5):1113.","journal-title":"Pharmaceutics"},{"issue":"8","key":"4020_CR61","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/17425247.2017.1247804","volume":"14","author":"W-H Lee","year":"2017","unstructured":"Lee W-H, et al. The achievement of ligand-functionalized organic\/polymeric nanoparticles for treating multidrug resistant cancer. Expert Opin Drug Deliv. 2017;14(8):937\u201357.","journal-title":"Expert Opin Drug Deliv"},{"key":"4020_CR62","doi-asserted-by":"crossref","unstructured":"Stack MS. EGF\/ErbB receptor family in ovarian cancer. In: Ovarian Cancer. 2002. p. 247\u201358.","DOI":"10.1007\/978-1-4757-3587-1_11"},{"key":"4020_CR63","doi-asserted-by":"crossref","unstructured":"Siu MK, et al. Paradoxical impact of two folate receptors, FR\u03b1 and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One. 2012;7(11):e47201.","DOI":"10.1371\/journal.pone.0047201"},{"issue":"4","key":"4020_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/0300891619839308","volume":"105","author":"D Lorusso","year":"2019","unstructured":"Lorusso D, et al. Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis. Tumori J. 2019;105(4):282\u20137.","journal-title":"Tumori J"},{"issue":"1","key":"4020_CR65","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1021\/acs.biomac.5b01189","volume":"17","author":"SK Jones","year":"2016","unstructured":"Jones SK, Lizzio V, Merkel OM. Folate receptor targeted delivery of siRNA and paclitaxel to ovarian cancer cells via folate conjugated triblock copolymer to overcome TLR4 driven chemotherapy resistance. Biomacromol. 2016;17(1):76\u201387.","journal-title":"Biomacromol"},{"key":"4020_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105663","author":"P Kesharwani","year":"2024","unstructured":"Kesharwani P, et al. \u03b1v\u03b23 integrin targeting RGD peptide-based nanoparticles as an effective strategy for selective drug delivery to tumor microenvironment. J Drug Deliv Sci Technol. 2024. https:\/\/doi.org\/10.1016\/j.jddst.2024.105663.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4020_CR67","doi-asserted-by":"publisher","first-page":"105614","DOI":"10.1016\/j.jddst.2024.105614","volume":"95","author":"G Kumar","year":"2024","unstructured":"Kumar G, et al. Trastuzumab-conjugated liposomes for co-delivery of paclitaxel and anti-abcb1 siRNA in HER2-positive breast cancer: in vitro and in vivo evaluations. J Drug Deliv Sci Technol. 2024;95:105614.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"4020_CR68","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1038\/srep08509","volume":"5","author":"X Yang","year":"2015","unstructured":"Yang X, et al. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep. 2015;5(1):8509.","journal-title":"Sci Rep"},{"issue":"14","key":"4020_CR69","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/smll.200801647","volume":"5","author":"C Fang","year":"2009","unstructured":"Fang C, et al. Functionalized nanoparticles with long-term stability in biological media. Small. 2009;5(14):1637.","journal-title":"Small"},{"issue":"11","key":"4020_CR70","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrd4333","volume":"13","author":"VP Torchilin","year":"2014","unstructured":"Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813\u201327.","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"4020_CR71","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.2174\/1381612825666190709221141","volume":"25","author":"K Saravanakumar","year":"2019","unstructured":"Saravanakumar K, et al. Emerging strategies in stimuli-responsive nanocarriers as the drug delivery system for enhanced cancer therapy. Curr Pharm Des. 2019;25(24):2609\u201325.","journal-title":"Curr Pharm Des"},{"key":"4020_CR72","unstructured":"de Freitas Martins C. Multi-targeted docetaxel polymeric nanoparticles as delivery systems for chemotherapy to treat glioblastoma. 2022, Universidade do Porto (Portugal)."},{"key":"4020_CR73","doi-asserted-by":"crossref","unstructured":"Serpe L et al. Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Pharmacogen Personal Med. 2014;31\u201342.","DOI":"10.2147\/PGPM.S58374"},{"key":"4020_CR74","doi-asserted-by":"crossref","unstructured":"Qamar Z et al. Receptor-mediated nose-to-brain delivery of drug combination-loaded polymeric nanocarriers for the treatment of glioblastoma-Current progress and future perspectives part I: Receptor-mediated nose-to-brain delivery approaches for glioblastoma. Exp Opin Drug Del. 2025;1\u201323.","DOI":"10.1080\/17425247.2025.2578384"},{"key":"4020_CR75","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jconrel.2018.05.012","volume":"283","author":"D van den Brand","year":"2018","unstructured":"van den Brand D, et al. siRNA in ovarian cancer\u2013delivery strategies and targets for therapy. J Control Release. 2018;283:45\u201358.","journal-title":"J Control Release"},{"issue":"2","key":"4020_CR76","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ymeth.2013.01.007","volume":"63","author":"MS Goldberg","year":"2013","unstructured":"Goldberg MS. SiRNA delivery for the treatment of ovarian cancer. Methods. 2013;63(2):95\u2013100.","journal-title":"Methods"},{"issue":"2","key":"4020_CR77","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4103\/0973-1482.153661","volume":"12","author":"H Mirzaei","year":"2016","unstructured":"Mirzaei H, et al. SiRNA and epigenetic aberrations in ovarian cancer. J Cancer Res Ther. 2016;12(2):498\u2013508.","journal-title":"J Cancer Res Ther"},{"issue":"147","key":"4020_CR78","doi-asserted-by":"publisher","first-page":"147ra112","DOI":"10.1126\/scitranslmed.3003778","volume":"4","author":"Y Ren","year":"2012","unstructured":"Ren Y, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med. 2012;4(147):147ra112-147ra112.","journal-title":"Sci Transl Med"},{"issue":"2","key":"4020_CR79","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/mt.2010.243","volume":"19","author":"P Tarapore","year":"2011","unstructured":"Tarapore P, et al. Application of phi29 motor prna for targeted therapeutic delivery of sirna silencing metallothionein-IIA and survivin in ovarian cancers. Mol Ther. 2011;19(2):386\u201394.","journal-title":"Mol Ther"},{"issue":"7","key":"4020_CR80","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/1535-7163.MCT-15-0100","volume":"14","author":"M Talekar","year":"2015","unstructured":"Talekar M, et al. Cosilencing of PKM-2 and MDR-1 sensitizes multidrug-resistant ovarian cancer cells to paclitaxel in a murine model of ovarian cancer. Mol Cancer Ther. 2015;14(7):1521\u201331.","journal-title":"Mol Cancer Ther"},{"key":"4020_CR81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.canlet.2016.03.045","volume":"387","author":"T Wang","year":"2017","unstructured":"Wang T, et al. Challenges and opportunities for siRNA-based cancer treatment. Cancer Lett. 2017;387:77\u201383.","journal-title":"Cancer Lett"},{"issue":"6","key":"4020_CR82","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2174\/156652309790031148","volume":"9","author":"T Kaur","year":"2009","unstructured":"Kaur T, Slavcev RA, Wettig SD. Addressing the challenge: current and future directions in ovarian cancer therapy. Curr Gene Ther. 2009;9(6):434\u201358.","journal-title":"Curr Gene Ther"},{"issue":"6","key":"4020_CR83","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1158\/1535-7163.MCT-16-0541","volume":"16","author":"MJ Wagner","year":"2017","unstructured":"Wagner MJ, et al. Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). Mol Cancer Ther. 2017;16(6):1114\u201323.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"4020_CR84","doi-asserted-by":"publisher","first-page":"2100287","DOI":"10.1002\/smll.202100287","volume":"17","author":"MS Singh","year":"2021","unstructured":"Singh MS, et al. Therapeutic gene silencing using targeted lipid nanoparticles in metastatic ovarian cancer. Small. 2021;17(19):2100287.","journal-title":"Small"},{"key":"4020_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/onco5010002","author":"C Sousa","year":"2025","unstructured":"Sousa C, Videira M. Dual approaches in oncology: the promise of siRNA and chemotherapy combinations in cancer therapies. Onco. 2025. https:\/\/doi.org\/10.3390\/onco5010002.","journal-title":"Onco"},{"key":"4020_CR86","unstructured":"Karim ME. Fabrication and evaluation of biodegradable inorganic-organic hybrid nanoparticles as potential tools for targeted delivery of genes and small interfering RNAs into breast cancer cells. 2019, Monash University."},{"issue":"9","key":"4020_CR87","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/biot.201100054","volume":"6","author":"JC Burnett","year":"2011","unstructured":"Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA\/shRNA therapeutics in clinical trials. Biotechnol J. 2011;6(9):1130\u201346.","journal-title":"Biotechnol J"},{"issue":"4","key":"4020_CR88","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"J Tabernero","year":"2013","unstructured":"Tabernero J, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406\u201317.","journal-title":"Cancer Discov"},{"issue":"1","key":"4020_CR89","volume":"2020","author":"Z Yang","year":"2020","unstructured":"Yang Z, Liu Z. The emerging role of microRNAs in breast cancer. J Oncol. 2020;2020(1):9160905.","journal-title":"J Oncol"},{"key":"4020_CR90","doi-asserted-by":"publisher","unstructured":"Zhao L, et al. The role of miRNA in ovarian cancer: an overview. Reprod Sci. 2022(10). https:\/\/doi.org\/10.1007\/s43032-021-00717-w.","DOI":"10.1007\/s43032-021-00717-w"},{"issue":"9","key":"4020_CR91","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3390\/ijerph16091510","volume":"16","author":"S-N Chen","year":"2019","unstructured":"Chen S-N, et al. Microrna in ovarian cancer: biology, pathogenesis, and therapeutic opportunities. Int J Environ Res Public Health. 2019;16(9):1510.","journal-title":"Int J Environ Res Public Health"},{"key":"4020_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1757-2215-5-44","volume":"5","author":"MS Zaman","year":"2012","unstructured":"Zaman MS, et al. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res. 2012;5:1\u201311.","journal-title":"J Ovarian Res"},{"issue":"1","key":"4020_CR93","doi-asserted-by":"publisher","first-page":"F77","DOI":"10.1677\/ERC-09-0203","volume":"17","author":"N Dahiya","year":"2010","unstructured":"Dahiya N, Morin PJ. Micrornas in ovarian carcinomas. Endocr Relat Cancer. 2010;17(1):F77-89.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4020_CR94","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ygyno.2011.03.026","volume":"122","author":"Q Wu","year":"2011","unstructured":"Wu Q, et al. Microrna-200a inhibits CD133\/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol. 2011;122(1):149\u201354.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4020_CR95","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ygyno.2009.08.009","volume":"116","author":"A Bendoraite","year":"2010","unstructured":"Bendoraite A, et al. Regulation of miR-200 family micrornas and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol. 2010;116(1):117\u201325.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4020_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-025-01623-4","volume":"18","author":"K Zhang","year":"2025","unstructured":"Zhang K, et al. MiR-34a-5p modulation of polycystic ovary syndrome via targeting the NOTCH signaling pathway. J Ovarian Res. 2025;18(1):55.","journal-title":"J Ovarian Res"},{"issue":"1","key":"4020_CR97","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/ijo.2016.3503","volume":"49","author":"R Gambari","year":"2016","unstructured":"Gambari R, et al. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: \u039dew trends in the development of miRNA therapeutic strategies in oncology. Int J Oncol. 2016;49(1):5\u201332.","journal-title":"Int J Oncol"},{"issue":"9","key":"4020_CR98","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/17460441.2020.1765770","volume":"15","author":"M Segal","year":"2020","unstructured":"Segal M, Slack FJ. Challenges identifying efficacious miRNA therapeutics for cancer. Expert Opin Drug Discov. 2020;15(9):987\u201391.","journal-title":"Expert Opin Drug Discov"},{"key":"4020_CR99","doi-asserted-by":"publisher","DOI":"10.1039\/D4NA00488D","author":"MP Fawzy","year":"2024","unstructured":"Fawzy MP, et al. Revolutionizing cancer therapy: nanoformulation of miRNA-34\u2013enhancing delivery and efficacy for various cancer immunotherapies: a review. Nanoscale Adv. 2024. https:\/\/doi.org\/10.1039\/D4NA00488D.","journal-title":"Nanoscale Adv"},{"key":"4020_CR100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS2597","author":"MS Beg","year":"2016","unstructured":"Beg MS, American Society of Clinical Oncology, et al. First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: phase Ia expansion in patients with advanced solid tumors. J Clin Oncol. 2016. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.TPS2597.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4020_CR101","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong DS, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630\u20137.","journal-title":"Br J Cancer"},{"issue":"11","key":"4020_CR102","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1039\/C5MD00365B","volume":"6","author":"S Gadde","year":"2015","unstructured":"Gadde S. Multi-drug delivery nanocarriers for combination therapy. Medchemcomm. 2015;6(11):1916\u201329.","journal-title":"Medchemcomm"},{"key":"4020_CR103","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jconrel.2019.10.047","volume":"315","author":"C Dai Phung","year":"2019","unstructured":"Dai Phung C, et al. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death. J Control Release. 2019;315:126\u201338.","journal-title":"J Control Release"},{"issue":"1","key":"4020_CR104","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12951-021-01139-1","volume":"19","author":"X Wang","year":"2021","unstructured":"Wang X, et al. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway. J Nanobiotechnology. 2021;19(1):444.","journal-title":"J Nanobiotechnology"},{"issue":"4","key":"4020_CR105","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14624","volume":"28","author":"HMAR Putri","year":"2024","unstructured":"Putri HMAR, et al. Microrna-mediated approaches in ovarian cancer therapy: a comprehensive systematic review. Oncol Lett. 2024;28(4):491.","journal-title":"Oncol Lett"},{"issue":"11","key":"4020_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03189-z","volume":"11","author":"X Dong","year":"2020","unstructured":"Dong X, et al. Exosomes and breast cancer drug resistance. Cell Death Dis. 2020;11(11):987.","journal-title":"Cell Death Dis"},{"issue":"15","key":"4020_CR107","doi-asserted-by":"publisher","first-page":"2103222","DOI":"10.1002\/advs.202103222","volume":"9","author":"JJ Lai","year":"2022","unstructured":"Lai JJ, et al. Exosome processing and characterization approaches for research and technology development. Adv Sci. 2022;9(15):2103222.","journal-title":"Adv Sci"},{"issue":"4","key":"4020_CR108","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1172\/JCI81135","volume":"126","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016;126(4):1208\u201315.","journal-title":"J Clin Invest"},{"issue":"8","key":"4020_CR109","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1111\/cas.13697","volume":"109","author":"YL Tai","year":"2018","unstructured":"Tai YL, et al. Exosomes in cancer development and clinical applications. Cancer Sci. 2018;109(8):2364\u201374.","journal-title":"Cancer Sci"},{"issue":"9","key":"4020_CR110","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.apsb.2021.01.001","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu J, et al. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B. 2021;11(9):2783\u201397.","journal-title":"Acta Pharm Sin B"},{"key":"4020_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00066","volume":"8","author":"C Rajagopal","year":"2018","unstructured":"Rajagopal C, Harikumar K. The origin and functions of exosomes in cancer. Front Oncol. 2018;8:66.","journal-title":"Front Oncol"},{"issue":"11","key":"4020_CR112","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/j.1742-4658.2012.08589.x","volume":"279","author":"W Cheng","year":"2012","unstructured":"Cheng W, et al. Microrna-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279(11):2047\u201359.","journal-title":"FEBS J"},{"issue":"11","key":"4020_CR113","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4155\/fmc-2021-0332","volume":"14","author":"Z Fong","year":"2022","unstructured":"Fong Z, Lee W-L. An emerging role of KRAS in biogenesis, cargo sorting and uptake of cancer-derived extracellular vesicles. Future Med Chem. 2022;14(11):827\u201345.","journal-title":"Future Med Chem"},{"key":"4020_CR114","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2021.05.031","volume":"517","author":"W-H Chang","year":"2021","unstructured":"Chang W-H, et al. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Cancer Lett. 2021;517:66\u201377.","journal-title":"Cancer Lett"},{"issue":"1","key":"4020_CR115","doi-asserted-by":"publisher","first-page":"11150","DOI":"10.1038\/ncomms11150","volume":"7","author":"CL Au Yeung","year":"2016","unstructured":"Au Yeung CL, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7(1):11150.","journal-title":"Nat Commun"},{"issue":"18","key":"4020_CR116","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2217\/nnm-2016-0154","volume":"11","author":"M Hadla","year":"2016","unstructured":"Hadla M, et al. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models. Nanomedicine. 2016;11(18):2431\u201341.","journal-title":"Nanomedicine"},{"issue":"1","key":"4020_CR117","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12951-022-01264-5","volume":"20","author":"L Li","year":"2022","unstructured":"Li L, et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnology. 2022;20(1):50.","journal-title":"J Nanobiotechnology"},{"key":"4020_CR118","doi-asserted-by":"publisher","unstructured":"Li X, et al. Challenges and opportunities in exosome research\u2014perspectives from biology, engineering, and cancer therapy. APL Bioeng. 2019. https:\/\/doi.org\/10.1063\/1.5087122.","DOI":"10.1063\/1.5087122"},{"key":"4020_CR119","doi-asserted-by":"publisher","DOI":"10.1039\/D3TB02752J","author":"S Madhan","year":"2024","unstructured":"Madhan S, Dhar R, Devi A. Plant-derived exosomes: a green approach for cancer drug delivery. J Mater Chem B. 2024. https:\/\/doi.org\/10.1039\/D3TB02752J.","journal-title":"J Mater Chem B"},{"issue":"15","key":"4020_CR120","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1080\/17435889.2025.2533107","volume":"20","author":"B Mangla","year":"2025","unstructured":"Mangla B, et al. Regulating nanomedicines: challenges, opportunities, and the path forward. Nanomedicine. 2025;20(15):1911\u201327.","journal-title":"Nanomedicine"},{"issue":"13","key":"4020_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132102","volume":"17","author":"G Colonna","year":"2025","unstructured":"Colonna G. Overcoming barriers in cancer biology research: current limitations and solutions. Cancers (Basel). 2025;17(13):2102.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4020_CR122","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","volume":"44","author":"MTD Martino","year":"2025","unstructured":"Martino MTD, Tagliaferri P, Tassone P. Microrna in cancer therapy: breakthroughs and challenges in early clinical applications. J Exp Clin Cancer Res. 2025;44(1):126.","journal-title":"J Exp Clin Cancer Res"},{"key":"4020_CR123","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/978-981-96-3041-7_25","volume-title":"RNA Therapeutics in Human Diseases","author":"PE Saw","year":"2025","unstructured":"Saw PE, Song E. Current Development of RNA Delivery Systems. In: RNA Therapeutics in Human Diseases. Springer; 2025. p. 591\u2013616."},{"issue":"1","key":"4020_CR124","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-025-02280-3","volume":"24","author":"R Aggarwal","year":"2025","unstructured":"Aggarwal R, et al. Understanding gold nanoparticles and their attributes in ovarian cancer therapy. Mol Cancer. 2025;24(1):88.","journal-title":"Mol Cancer"},{"issue":"1","key":"4020_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02215-4","volume":"24","author":"J Li","year":"2025","unstructured":"Li J, Wang J, Chen Z. Emerging role of exosomes in cancer therapy: progress and challenges. Mol Cancer. 2025;24(1):13.","journal-title":"Mol Cancer"},{"key":"4020_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjprs.2025.05.001","author":"H Chen","year":"2025","unstructured":"Chen H, Li Q. Recent advances in scalable exosome production: challenges and innovations. Chin J Plast Reconstr Surg. 2025. https:\/\/doi.org\/10.1016\/j.cjprs.2025.05.001.","journal-title":"Chin J Plast Reconstr Surg"},{"issue":"8","key":"4020_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17080990","volume":"17","author":"N Verma","year":"2025","unstructured":"Verma N, Arora S. Navigating the global regulatory landscape for exosome-based therapeutics: challenges, strategies, and future directions. Pharmaceutics. 2025;17(8):990.","journal-title":"Pharmaceutics"},{"key":"4020_CR128","doi-asserted-by":"publisher","first-page":"1677088","DOI":"10.3389\/fimmu.2025.1677088","volume":"16","author":"MA Ansarian","year":"2025","unstructured":"Ansarian MA, et al. Exosomal biomarkers in leukemia: translational potential and regulatory challenges for precision medicine applications. Front Immunol. 2025;16:1677088.","journal-title":"Front Immunol"},{"key":"4020_CR129","doi-asserted-by":"crossref","unstructured":"Colonna G. Unravelling the Barriers: Current Limitations in Cancer Biology Research and How to Overcome Them. 2025.","DOI":"10.20944\/preprints202505.1837.v1"},{"key":"4020_CR130","unstructured":"Tinger L. Development of an integrated platform for personalized cancer treatment: diagnostic and therapeutic solutions based on biomarkers and nanotechnology. 2024."},{"issue":"3","key":"4020_CR131","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/bioengineering10030292","volume":"10","author":"P Sebbagh","year":"2023","unstructured":"Sebbagh P, et al. Current status of PRP manufacturing requirements & European regulatory frameworks: practical tools for the appropriate implementation of PRP therapies in musculoskeletal regenerative medicine. Bioengineering. 2023;10(3):292.","journal-title":"Bioengineering"},{"key":"4020_CR132","first-page":"058","volume":"2","author":"MA Afolabi","year":"2024","unstructured":"Afolabi MA, Olisakwe HC, Igunma TO. A conceptual framework for designing multi-functional catalysts: bridging efficiency and sustainability in industrial applications. Global J Res Multidisc Stud. 2024;2:058\u201366.","journal-title":"Global J Res Multidisc Stud"},{"issue":"1","key":"4020_CR133","doi-asserted-by":"publisher","first-page":"2605387","DOI":"10.1080\/10717544.2025.2605387","volume":"33","author":"X Xu","year":"2026","unstructured":"Xu X, et al. Nanotherapeutics for enhanced treatments for ovarian cancer: a comprehensive minireview. Drug Deliv. 2026;33(1):2605387.","journal-title":"Drug Deliv"},{"key":"4020_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102309","volume":"31","author":"EM Miller","year":"2021","unstructured":"Miller EM, Samec TM, Alexander-Bryant AA. Nanoparticle delivery systems to combat drug resistance in ovarian cancer. Nanomedicine Nanotechnol Biol Med. 2021;31:102309.","journal-title":"Nanomedicine Nanotechnol Biol Med"},{"key":"4020_CR135","unstructured":"Network NCC. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 1. in Plymouth Meeting. 2017."},{"key":"4020_CR136","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","volume":"130","author":"EN Hoogenboezem","year":"2018","unstructured":"Hoogenboezem EN, Duvall CL. Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev. 2018;130:73\u201389.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"4020_CR137","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jconrel.2011.11.015","volume":"157","author":"K Park","year":"2011","unstructured":"Park K. Albumin: a versatile carrier for drug delivery. J Control Release. 2011;157(1):3\u20133.","journal-title":"J Control Release"},{"issue":"9","key":"4020_CR138","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1200\/JCO.2008.18.9548","volume":"27","author":"MG Teneriello","year":"2009","unstructured":"Teneriello MG, et al. Phase II evaluation of nanoparticle albumin\u2013bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2009;27(9):1426\u201331.","journal-title":"J Clin Oncol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04020-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04020-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04020-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:01:23Z","timestamp":1783634483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04020-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":138,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4020"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04020-8","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest. The views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy or position of Novartis or any of its affiliates or officers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}